Pfm Health Sciences, LP Fate Therapeutics Inc Transaction History

Pfm Health Sciences, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $11.8 Million - $18.3 Million	-881,002 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $10.3 Million - $15 Million	-666,728 Reduced 43.08%	881,002 $13.7 Million
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $4.16 Million - $5.44 Million	266,194 Added 20.77%	1,547,730 $31.4 Million
Q1 2019 May 15, 2019	SELL	$13.15 - $18.71 $2.49 Million - $3.54 Million	-189,464 Reduced 12.88%	1,281,536 $22.5 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $347,361 - $513,780	-30,258 Reduced 2.02%	1,471,000 $18.9 Million
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $13.1 Million - $24.5 Million	1,501,258 New	1,501,258 $24.5 Million

166

101M

41.3K

15.9K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.